These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 26483076)

  • 1. Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy.
    Kyhl LE; Li S; Faerch KU; Soegaard B; Larsen F; Areberg J
    Br J Clin Pharmacol; 2016 Feb; 81(2):290-300. PubMed ID: 26483076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing.
    Ingman K; Hagelberg N; Aalto S; Någren K; Juhakoski A; Karhuvaara S; Kallio A; Oikonen V; Hietala J; Scheinin H
    Neuropsychopharmacology; 2005 Dec; 30(12):2245-53. PubMed ID: 15956985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence.
    Walker BM; Koob GF
    Neuropsychopharmacology; 2008 Feb; 33(3):643-52. PubMed ID: 17473837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetics of nalmefene after a single or multiple intravenous doses in Chinese healthy volunteers].
    Liao RF; Zeng ZP; Wen YG
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct; 28(10):1816-9. PubMed ID: 18971181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?
    Bart G; Schluger JH; Borg L; Ho A; Bidlack JM; Kreek MJ
    Neuropsychopharmacology; 2005 Dec; 30(12):2254-62. PubMed ID: 15988468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of liver disease on the disposition of the opioid antagonist nalmefene.
    Frye RF; Matzke GR; Schade R; Dixon R; Rabinovitz M
    Clin Pharmacol Ther; 1997 Jan; 61(1):15-23. PubMed ID: 9024170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study.
    Quelch DR; Mick I; McGonigle J; Ramos AC; Flechais RSA; Bolstridge M; Rabiner E; Wall MB; Newbould RD; Steiniger-Brach B; van den Berg F; Boyce M; Østergaard Nilausen D; Breuning Sluth L; Meulien D; von der Goltz C; Nutt D; Lingford-Hughes A
    Biol Psychiatry; 2017 Jun; 81(11):941-948. PubMed ID: 28216062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system.
    Kim S; Wagner HN; Villemagne VL; Kao PF; Dannals RF; Ravert HT; Joh T; Dixon RB; Civelek AC
    J Nucl Med; 1997 Nov; 38(11):1726-31. PubMed ID: 9374341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacological profile and clinical findings of nalmefene (Selincro
    Tadori Y
    Nihon Yakurigaku Zasshi; 2020; 155(2):113-119. PubMed ID: 32115477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of nalmefene in plasma by high-performance liquid chromatography with electrochemical detection and its application in pharmacokinetic studies.
    Chou JZ; Albeck H; Kreek MJ
    J Chromatogr; 1993 Apr; 613(2):359-64. PubMed ID: 8491826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Influence of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Naldemedine.
    Fukumura K; Yamada T; Yokota T; Kawasaki A
    Clin Pharmacol Drug Dev; 2020 Feb; 9(2):162-174. PubMed ID: 30977959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence.
    Mason BJ; Salvato FR; Williams LD; Ritvo EC; Cutler RB
    Arch Gen Psychiatry; 1999 Aug; 56(8):719-24. PubMed ID: 10435606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of age on the pharmacokinetics of the opioid antagonist nalmefene.
    Frye RF; Matzke GR; Jallad NS; Wilhelm JA; Bikhazi GB
    Br J Clin Pharmacol; 1996 Sep; 42(3):301-6. PubMed ID: 8877019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential.
    Soyka M
    Expert Opin Pharmacother; 2016; 17(4):619-26. PubMed ID: 26810044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects.
    Weerts EM; Kim YK; Wand GS; Dannals RF; Lee JS; Frost JJ; McCaul ME
    Neuropsychopharmacology; 2008 Feb; 33(3):653-65. PubMed ID: 17487229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of renal insufficiency and hemodialysis on the pharmacokinetics of nalmefene.
    Matzke GR; Frye RF; Alexander AC; Reynolds R; Dixon R; Johnston J; Rault RM
    J Clin Pharmacol; 1996 Feb; 36(2):144-51. PubMed ID: 8852390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nalmefene for the treatment of alcohol dependence: a current update.
    Soyka M
    Int J Neuropsychopharmacol; 2014 Apr; 17(4):675-84. PubMed ID: 24246244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependence.
    Dunbar JL; Turncliff RZ; Hayes SC; Farrell CB
    J Stud Alcohol Drugs; 2007 Nov; 68(6):862-70. PubMed ID: 17960304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose.
    Krieter P; Gyaw S; Crystal R; Skolnick P
    J Pharmacol Exp Ther; 2019 Nov; 371(2):409-415. PubMed ID: 30940694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats.
    June HL; Grey C; Warren-Reese C; Durr LF; Ricks-Cord A; Johnson A; McCane S; Williams LS; Mason D; Cummings R; Lawrence A
    Alcohol Clin Exp Res; 1998 Dec; 22(9):2174-85. PubMed ID: 9884166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.